Cargando…
CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
Kidneys are one of the most frequently transplanted human organs. Immunosuppressive agents may prevent or reverse most acute rejection episodes; however, the graft may still succumb to chronic rejection. The immunological response involved in the chronic rejection process depends on both innate and...
Autores principales: | Silva, Marcos V., Machado, Juliana R., Rocha, Laura P., Castellano, Lúcio R., Reis, Marlene A., Corrêa, Rosana R. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376773/ https://www.ncbi.nlm.nih.gov/pubmed/22720132 http://dx.doi.org/10.1155/2012/203780 |
Ejemplares similares
-
Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
por: Ippoliti, Giovanbattista, et al.
Publicado: (2012) -
Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells
por: de Graav, Gretchen N., et al.
Publicado: (2016) -
Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation
por: Gupta, Gaurav, et al.
Publicado: (2010) -
Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation
por: Zhang, Hengcheng, et al.
Publicado: (2021) -
An Overview of Molecular Mechanism of Nephrotic Syndrome
por: Machado, Juliana Reis, et al.
Publicado: (2012)